All In Biotech

Drug Trial Radar · NCT07861074

A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)

A Phase 2b, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Noninfectious Intermediate, Posterior, or Panuveitis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

87

Planned (sponsor's estimate)

Start

Nov 4, 2026

Primary completion

Jun 5, 2029

Study completion Apr 10, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time. In this trial, researchers will look at different doses (amounts) of tulisokibart. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until NIIPPU gets worse. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.

Conditions

  • Noninfectious Intermediate, Posterior, or Panuveitis

Interventions

  • TulisokibartDrug

    Subcutaneous (SC) administration

  • PlaceboDrug

    SC administration

  • Background prednisone therapyDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Treatment Failure Occurring on or After Week 6 Through Week 50Time frame: up to 44 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Texas Retina Associates ( Site 0006)

    Plano, Texas · Recruiting

  • West Coast Retina Consultants - West Broadway ( Site 0505)

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.